Profile data is unavailable for this security.
About the company
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
- Revenue in GBP (TTM)89.54m
- Net income in GBP-157.49m
- Incorporated1996
- Employees714.00
- LocationOxford Biomedica PLCWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
- Phone+44 186 578 3000
- Fax+44 186 578 3001
- Websitehttps://www.oxb.com/
More ▼
Mergers & acquisitions
| Acquired company | OXB:LSE since announced | Transaction value |
|---|---|---|
| ABL Europe SAS | 56.63% | 16.02m |
Data delayed at least 20 minutes, as of Jul 30 2024 08:02 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Futura Medical PLC | 3.10m | -6.51m | 102.11m | 12.00 | -- | 18.61 | -- | 32.93 | -0.0219 | -0.0219 | 0.0105 | 0.0182 | 0.3391 | -- | 5.09 | 258,414.20 | -71.22 | -79.25 | -127.75 | -127.22 | 57.22 | -- | -210.03 | -914.37 | 1.47 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Scancell Holdings Plc | 0.00 | -11.32m | 132.47m | 51.00 | -- | -- | -- | -- | -0.0138 | -0.0138 | 0.00 | -0.0102 | 0.00 | -- | -- | 0.00 | -37.31 | -33.32 | -40.52 | -35.82 | -- | -- | -- | -817.98 | -- | -- | 1.73 | -- | -- | -- | -161.24 | -- | 77.85 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.10m | 159.48m | 34.00 | -- | -- | -- | -- | -0.2807 | -0.2807 | 0.00 | -0.1304 | 0.00 | -- | -- | 0.00 | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| 4Basebio PLC | 506.00k | -7.67m | 184.47m | -- | -- | -- | -- | 364.57 | -0.6222 | -0.6222 | 0.0411 | -0.0399 | 0.0429 | 0.714 | 6.29 | -- | -64.93 | -- | -77.36 | -- | 67.19 | -- | -1,514.82 | -- | 2.06 | -26.66 | 1.05 | -- | 88.81 | -- | -48.83 | -- | -- | -- |
| hVIVO PLC | 56.04m | 16.12m | 202.41m | 274.00 | 12.72 | 5.90 | 10.75 | 3.61 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Bioventix PLC | 13.60m | 8.67m | 224.45m | 16.00 | 26.34 | 19.63 | 25.54 | 16.51 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
| Allergy Therapeutics plc | 53.26m | -50.22m | 228.79m | 635.00 | -- | 8.65 | -- | 4.30 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Avacta Group Plc | 23.25m | -24.95m | 258.51m | 154.00 | -- | -- | -- | 11.12 | -0.0914 | -0.0914 | 0.0853 | -- | -- | -- | -- | 150,954.50 | -- | -- | -- | -- | 48.37 | -- | -107.31 | -- | -- | -0.575 | -- | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| Oxford BioMedica plc | 89.54m | -157.49m | 387.52m | 714.00 | -- | 4.81 | -- | 4.33 | -1.63 | -1.63 | 0.9273 | 0.7645 | 0.2513 | 3.91 | 3.07 | 125,404.80 | -51.69 | -19.60 | -64.26 | -24.68 | 44.37 | 50.74 | -205.68 | -44.38 | 2.90 | -22.92 | 0.5888 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Puretech Health PLC | 2.59m | -51.04m | 425.44m | 90.00 | -- | 1.34 | -- | 164.45 | -0.1832 | -0.1832 | 0.0093 | 1.33 | 0.0048 | -- | 0.4676 | 28,744.56 | -9.54 | 4.92 | -10.67 | 5.94 | -- | -- | -2,000.84 | 352.67 | -- | -- | 0.0524 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Genus plc | 673.10m | 33.40m | 1.22bn | 3.48k | 36.53 | 2.12 | 15.81 | 1.81 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
Data as of Jul 30 2024. Currency figures normalised to Oxford Biomedica PLC's reporting currency: UK Pound GBX
40.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Vulpes Investment Management Pte Ltd.as of 23 Oct 2023 | 8.44m | 8.02% |
| Liontrust Investment Partners LLPas of 15 Mar 2023 | 8.04m | 7.64% |
| BlackRock Investment Management (UK) Ltd.as of 18 Jul 2024 | 5.15m | 4.89% |
| M&G Investment Management Ltd.as of 15 Mar 2023 | 5.07m | 4.81% |
| Global Alpha Capital Management Ltd.as of 15 Mar 2023 | 3.88m | 3.69% |
| Charles Schwab Investment Management, Inc.as of 01 Jun 2024 | 3.13m | 2.97% |
| Hargreaves Lansdown Asset Management Ltd.as of 15 Mar 2023 | 3.03m | 2.88% |
| The Vanguard Group, Inc.as of 15 Mar 2023 | 2.71m | 2.58% |
| Banque Pictet & Cie SAas of 01 Jun 2024 | 1.92m | 1.82% |
| Threadneedle Asset Management Ltd.as of 01 Jun 2024 | 1.56m | 1.49% |
More ▼
Data from 31 Mar 2024 - 01 Jul 2024Source: FactSet Research Systems Inc.
